Published Aug 19, 2026, 10:00 PM ET · Updated 3 months ago · 1 source

Moderna's personalized mRNA vaccine success in melanoma treatment is a significant positive catalyst

Youtube

Original Report

Moderna's personalized mRNA vaccine, developed with Merck, demonstrated a 50% reduction in melanoma recurrence and spread when added to Keytruda in Phase 3 trials, which is an amazing positive outcome and a significant catalyst for the company.